Kura Oncology falls despite trial success; rival Syndax gains
Syndax Pharma (SNDX) stock rose after Kura Oncology (KURA) posted a mid-stage trial win for a leukemia drug is similar to ...
FierceBiotech3 天
Kura and Kyowa hail phase 2 win for leukemia drug soon heading to FDA, but hold back data
Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...
BioSpace3 天
Kura Eyes FDA Filing After Pivotal AML Win, but Investors Aren’t Impressed
Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.
HURA: Initiating an Immune Response
HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...
生物通6 天
用于预测急性髓系白血病全幻灯片图像基因突变的无注释深度学习
AML 作为一种侵袭性血液恶性肿瘤，具有显著的生物学和临床异质性，精准的风险分层对优化治疗效果、减少治疗相关并发症至关重要。目前，细胞遗传学变化和基因突变已被用于风险分层，其中 NPM1 和 FLT3-ITD 是 AML 患者中最常见的复发性基因突变 。然而，对这些突变进行分子检测存在诸多挑战，如不同机构资源和实验室基础设施差异大，限制了检测的可及性，延长了检测周转时间。